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This short review explores the large gap between clinical issues and basic science,
and suggests why tuberculosis research should focus on redirect the immune system
and not only on eradicating Mycobacterium tuberculosis bacillus. Along the manuscript,
several concepts involved in human tuberculosis are explored in order to understand
the big picture, including infection and disease dynamics, animal modeling, liquefaction,
inflammation and immunomodulation. Scientists should take into account all these factors
in order to answer questions with clinical relevance. Moreover, the inclusion of the concept
of a strong inflammatory response being required in order to develop cavitary tuberculosis
disease opens a new field for developing new therapeutic and prophylactic tools in which
destruction of the bacilli may not necessarily be the final goal.
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Along this short review, we would like to explore the gap between
medical doctors and basic scientists in terms of their point of view
regarding the tuberculosis disease (TBD), to revise several con-
cepts involved in human tuberculosis including the problems of
experimental modeling, and to point out why we shall consider
including immunomodulation in novel treatment strategies.
AN OVERVIEW OF TB RESEARCH, A TENDENTIOUS FOCUS
ON THE BACILLUS
Since the significant renewal of interest in TB research in the
early 1990s, work in this field has tended to focus on the eradi-
cation of Mycobacterium tuberculosis at different biological scales.
Concentrating specifically on the nature of the bacillus, and as
a direct result of the development of the whole field of “-omics”
resources, significant efforts have been expended to identify
metabolic pathways that may be susceptible to targeting by drugs
and to discern its role in terms of identification by the host’s
immune system (Brennan, 2003). One of the major victories in
this regard has been the identification of the paramount role of
ESAT-6 in terms of identification by the immune response, viru-
lence, and its absence in the BCG vaccine (Andersen and Doherty,
2005).
At a cellular scale, the hottest topic has involved discern-
ing how the bacillus is able to subvert both the innate immune
response, by manipulating the different mechanisms designed to
kill, or at least detect the presence of pathogens; and the adaptive
immune response, by delaying its induction or masking detec-
tion of the bacilli (Flynn and Chan, 2001; Axelrod et al., 2008).
In this regard, a great deal of research has focused on the main
actor, namely the alveolar macrophage and, of course, the den-
dritic cells (Egen et al., 2008; Korbel et al., 2008; Farinacci et al.,
2012; Kapina et al., 2013). Neutrophils have proven a less attrac-
tive target, although there are always peaks of data highlighting
their role (Tan et al., 2006; Martineau et al., 2007; D’Avila et al.,
2008), probably because of their low survival times, which makes
difficult to detect a relationship with M. tuberculosis and it’s long
doubling time. Another chapter in this field concerns the role of
fibroblasts, mainly because of their excellent behavior as “ex vivo”
systems (Hernandez-Pando et al., 2000; Gonzalez-Avila et al.,
2009). Indeed, it appears that fibroblasts could be the hidden link
that explains the invisibility of the bacilli during certain phases of
an infection. However, this proposal is currently awaiting valida-
tion in “in vivo” models. A similar situation is found for epithelial
or endothelial cells, although very little attention has been paid
to the paracrine role of these cells (Coma et al., 2006). In this
regard, it is not been clearly established that M. tuberculosis is a
slow organism (Cox, 2004) and that the “lack of quickness” of the
host might be proportional to the slow speed of the pathogen.
The tissue scale has been largely influenced by the presence
of hypoxia in the necrotic tissues that surround bacilli in a typ-
ical lesion, with an elegant concept coming from the “in vitro”
acellular experiences of the group of Wayne and the ability of the
bacilli to adapt to this stressful environment by becoming dor-
mant or non-replicating (Wayne, 1994). Although this has led to
the development of new drugs and “sterilizing” vaccines, this idea
has not been well contrasted with the usual oxygen levels at which
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subcellular structures work (Mochizuki, 1990). The conclusion
is that, like many other intracellular pathogens, M. tuberculosis
always lives under hypoxic conditions, either when inside an iso-
lated cell or when in a granuloma, whereas the high aerobiosis
present in laboratory flasks is completely artificial. The concept
of persistency is more intriguing as there is a point at which
drugs become less and less effective. This seems to be related to
some sort of adaptation to the environment mechanism of the
bacilli rather than to the acquisition of resistance(Gomez and
McKinney, 2004; Dhar and McKinney, 2010). As such, the ques-
tion arises as to whether this phenomenon could be related to
some type of interaction between drugs and tissues, or even the
interaction of drugs with the immune system.
In this regard, there is little information at the intersection of
what are currently considered to be two distinct worlds: the vac-
cine and the chemotherapy one. As such, very little effort has
been devoted to understanding how the immune response can
influence the mechanism of action of chemotherapy, and vice
versa.
At the “in vivo” scale, one of the main drivers of experimen-
tal modeling is the need to obtain a prophylactic or therapeutic
strategy able to reduce the bacillary load, even if since now this
has not been linked to the avoidance of infection, or at least lead
to a minimal peak in bacillary load followed by sterilization of the
tissues (Jung et al., 2005).
The concept of virulence can be located at this level. It is widely
considered that a virulent strain is one with a high ability to dis-
seminate throughout the population. However, the only way to
quantify this is bymolecularly characterizing strains isolated from
active tuberculosis cases. In contrast, the laboratory concept of
virulence, or “fitness”, has always been related to the speed of
bacillary growth in an acellular medium (Comas et al., 2012); or
in cellular systems (Rey-Jurado et al., 2011) or tissues in the case
of “in vivo” modeling (Caceres et al., 2012). This latter definition
should perhaps be reconsidered.
THE CLINICAL VIEWPOINT
On the other hand, clinicians focus on a very different aspects of
human tuberculosis, basically in detecting and treating a case of
TBD as soon as possible, as from a medical point of view, there is
no risk to life and no risk of transmission in the absence of TBD
(Long and Faust, 1941; Rieder et al., 1989).
To be more precise, a clinician’s first wish would probably be
to have the quickest possible test, with a high specificity and sen-
sitivity for TBD detection, in order to be able to apply it routinely
without depending on the semiology of the disease in the sub-
ject. In this regard, the paradox is that TBD seems to surpass
the clinical challenge of making a good diagnostic orientation—
the problem is that big and the symptomatology of TBD that
non-specific and confusing—. Indeed, regions with a high inci-
dence, MD students are instructed to consider TB when faced
with almost any sort of symptom: “TBD can be anything: TBD
must be suspected when facing any clinical case” (Zenner et al.,
2013).
On the need of new treatment options, it implies the need for
a good geopolitical environment first, which might be a big prob-
lem. In terms of the current available treatments, we still might
learn a lot and could ameliorate them. Moreover, anybody out
from the field could consider the current priority of the WHO,
namely the Directed Observed Treatment Strategy (DOTS) (Cox
et al., 2008) as “throwing in the towel”. It is not the case. Still what
is needed is a clearer and more focused view of the main prob-
lem, which is a better distribution and adhesion to the current
standard chemotherapy.
In this sense, to reduce the treatment to 15 days only would be
ideal. However, how canwe do this without having a robust exper-
imental model of TBD? A similar problem is found in diagnostics:
how are we going to develop a new and robust test without a good
experimental model of evolution towards TBD?
THE PROBLEM OF MODELING EXPERIMENTAL TBD
Surprisingly, there is still no robust and validated model of exper-
imental TBD. Moreover, a structured theory of how TBD can be
induced is also lacking and yet evenmore incredible is the absence
of an open and dynamic discussion about this subject. Overall,
there is as yet no open dialog between the clinical and experimen-
tal worlds: apparently, the experimental world seeks the answers
to questions that are of little interest to the clinical one.
In the new era of TB research, the most widely used exper-
imental animal model is the one popularized by Ian Orme, at
Colorado State University (Orme, 2005). This is a very easy and
robust murine model which can be induced by a low dose aerosol,
using aMiddlebrook device, and is thus highly reproducible. How
we can determine whether a mouse has an infection or disease?
The only reliable way is to recall an empirical data based on 60
years’ experience of using INH alone for the treatment of infec-
tion (Comstock, 1999). As this treatment does not cause INH
resistance (Balcells et al., 2006), we suppose in this case that
the subject has a bacillary load of less than 5 log10, which is
the concentration at which spontaneous mutations are induced
(Rastogi and David, 1993). Then, this model provides an acute
phase in which the bacillary load reaches similar levels to those
found in a mild TBD (from 6 to 7 log10), with the chronic phase
being reached when the bacillary load is controlled to around 5–6
log10 (Cardona et al., 1999), which is the higher boundary of the
infective level.
Thus, in terms of bacillary load, this model includes the pro-
gression from infection to active (mild) disease but lacks one vital
aspect, namely the induction of a human-like lesion. For this
reason, we concluded some time ago that, in contrast to the com-
monly held belief in the experimental modeling community, mice
are “tolerant” to M. tuberculosis infection (Cardona, 2006) rather
than being resistant (Cardona, 2010) as they can “live with the
bacilli” whilst being weakly “provoked” by it. In other words, they
exhibit a proportional immune response that is able to control
bacillary concentration without generating a marked lesion and,
more importantly, with little or no necrosis, depending on the
bacillary strain used (Cardona et al., 2003; Gil et al., 2006).
This is the most important handicap of this model as TB
lesions in humans are characterized by the generation of a large
quantity of necrotic tissue with a very low bacillary load. In this
regard, humans tolerate the presence of bacilli very badly, in other
words, bacilli are very provocative and trigger an extraordinary
and non-proportional inflammatory response in human tissues.
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EXPERIMENTAL MODELING TBD: LIQUEFACTION IS
THE CLUE
The tissue destruction in human TBD is so big that the character-
istic lesion in adults is the cavity (Canetti, 1955; Grosset, 2003).
This means that the necrotic process has been followed by liq-
uefaction and, once eroded, subsequent mass drainage toward
the bronchial tree. Traditionally, liquefaction and cavitation are
“. . . nature’s more rapid but more hazardous manner of eradi-
cating the disease” (Lurie et al., 1955). Max Lurie devoted all
his life to the study of TBD in a model that was able to repro-
duce both liquefaction and cavitation, thus effectively mimicking
what happens in humans. Lurie was able to establish two dif-
ferent colonies of rabbits: resistant and susceptible. The former
were able to develop cavitation and heal and had better survival
rates than the latter, which did not develop cavitation and had
much higher mortality rates. This model also confirmed that cav-
ities preferably develop in the apical lobes by way of experiments
which showed that keeping M. tuberculosis infected rabbits erect
in a harness for 11 h each day produced cavities in the upper lobes
rather than in the back of the lungs (Medlar and Sasano, 1936).
Lurie’s work was unfortunately truncated after losing both
colonies in a disastrous fire. However, Arthur Dannenberg inher-
ited his legacy and extended his experiments, building a struc-
tured theory about the evolution from infection to disease
(Converse et al., 1996; Dannenberg, 2006). Unfortunately, various
mechanistic concepts were difficult to substantiate in this theory
as this would require a relatively large investment to develop the
tools needed to do so and integrate the model with updated con-
cepts in immunology. The rabbit model of Lurie and Dannenberg
has been largely substituted by the mouse model, which helps us
to understand the process of infection and immune acquisition
againstM. tuberculosis (Cooper, 2009) but gives no clue as regards
the induction of TBD. The reason is that although this model is
not able to develop human-like lesions, it has been useful enough
to define synergies among drugs and define the length of the
treatment required to sterilize the lesions (Lecoeur et al., 1989).
Technically speaking, the behavior of the extracellular population,
present in the necrotic tissues and growing in the liquefacted tis-
sue, could be determined using “in vitro” systems. Indeed, it was
Jacques Grosset, probably one of the most experienced TB exper-
imental modelers ever, who highlighted from the very beginning
the interest in softening necrotic tissue to allow the entry of oxy-
gen and induce active extracellular growth of the bacilli in the
liquefacted product (Grosset, 1980, 2003).
LIQUEFACTION? CAVITATION? IS EVERYTHING ABOUT
DYNAMICITY?
Recent clinical trials have failed to demonstrate the sterilizing
activity of moxifloxacin, which would be key for reducing the
length of TBD treatment (Jawahar et al., 2013). These clinical tri-
als were conducted on the basis of predictions made using the
mouse model (Nuermberger et al., 2004). Because of that, this
could be a good opportunity to highlight about the importance to
invest in better models developing human-like lesions, especially
as regards cavity induction.
The experimental guinea pig model was also been pro-
moted in light of its ability to develop human-like lesions with
intragranulomatous necrosis, although it is unable to develop
liquefaction and cavitation (McMurray et al., 1996). The extensive
work undertaken in macaques, remarcable because its evolution-
ary proximity to humans, also deserves a mention. Unfortunately,
and even if they being so close to humans, macaques have not
proven to be robust enough in terms of defining the evolution
toward cavitation—the model being unable to make a good pre-
diction of its induction. Pathology evaluation is usually defined
after “pathology scoring” (Langermans et al., 2001; Capuano
et al., 2003; Verreck et al., 2009), a difficult-to-follow concept that,
in the end, reflects an inability to reproduce what finally hap-
pens in humans: as no equivalence has been drawn between this
pathology scoring and what has been described for more than a
century in Pathology Departments.
PET studies have given some degree of dynamicity to the pro-
cess. The ability to observe the same subject using such a potent
imaging technology, allows the same lesion to be monitored over
time. This experience has been so stimulating that it has led the
authors to enlist different phases in the evolution from infection
to disease (Barry et al., 2009). However, this raises the question
of the relevance of the concept named “rephasing”. The previ-
ous distinction between infection and disease provided definitive
support to the clinician when deciding to treat with one drug (in
those countries where it is affordable) or three or more drugs in
order to avoid the induction of drug resistance. So what is the use
of this rephasing? Would it not be more interesting to look at the
evolution towards cavitation in experimental models like the one
developed in rabbits?
EXPERIMENTAL MODELING: THE ANATOMY AND THE
VOLUME MIGHT BE CRUCIAL
Interestingly enough, other groups of modelers have appeared,
producing two new models, using goats and cows (Buddle et al.,
2005; Domingo et al., 2009; de Val Perez et al., 2011), in which
cavitation can be effectively induced and also the infection can be
effectively contained, resembling human-like behavior. The grow-
ing problem of TB in cattle has permitted to even use the models
letting natural infection happen by leaving ill subjects within the
herd to infect healthy ones(Ameni et al., 2010).
Finally, another model using minipigs was developed based on
the concept that a big animal should be less tolerant to bacilli than
a small one (Cardona, 2006, 2010), as a cavity could be never
reproduced in a mouse because it would be larger than the ani-
mal’s entire body. In this regard, what changes in a large compared
to a small mammal is not the size of the cells but the size of their
organs, in other words it is simply a question of economy and the
ability of large animals to “cut from healthy tissue” to stop the
infection progression.
With this aim in mind we started to work with “specific
pathogen free” (spf) minipigs in order to avoid any interfer-
ence from the natural infections that usually occur in even the
healthiest animals. To our dismay, these minipigs were unable to
induce cavitated lesions, at least in the period of study (up to
23 weeks)(Gil et al., 2010) and small lesions (of the same size
as those found in mice, from 0.5 to 2mm of diameter) were
found instead. However, these lesions tended to be encapsulated
even being so small, demonstrating the presence of a profibrotic
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environment in their lungs. This was related to the intralobular
septae, a lung structure never been taken into account in the field
of TB previously. This structure is only present in the lungs of
large mammals (thus being absent in mice, guinea pigs, rabbits or
macaques) including humans, with the aim to permit the expan-
sion of such a big organ, and thus helping respiratory function
(Fraser, 2005). As for any other collagen-based structure, these
septae are very sensitive to mechanical stress and quickly tend to
encapsulate any lesion present in the lung, even if only 0.5mm in
diameter.
TBD AND ITS INFLAMMATORY COMPONENT AS THE
ORIGIN OF THE LIQUEFACTIVE NECROSIS. MORE ON
EXPERIMENTAL MODELING
After many years considering the origin of liquefaction in terms
of a fight between profibrotic and antifibrotic mechanisms
(Cardona, 2011), we came to realize that the real problem might
be mechanical. In light of this, how can the progression of the
lesions can be explained? Lesions must evolve from 0.5 to 25mm,
the size at which a lesion has a greater probability of becom-
ing cavitated according to clinical data (Grenville-Mathers, 1947)
(Figure 1A).
While studying a mouse model able to develop liquefaction,
we identified the data of Kramnik et al. (Yan et al., 2006), who
described a model with a similar size of necrosis to the one we
experimentally obtained after a short treatment of infected SCID
mice (Guirado et al., 2006). At that point we realized that lique-
faction was induced in the lesions, but we wanted to reproduce it
more robustly as it has seldom been noticed previously in older
experiments with Swiss outbred mice (Marzo et al., 2013).
As a result, we started to work with C3HeBe/FeJ mice (those
used by the group of Kramnik) and soon realized that a large
necrosis was induced in a reproducible manner and that liq-
uefaction occurred as happened in both SCID and Swiss mice.
After effectively confirming the reproducibility of the induction
of liquefacted lesions, we decided to characterize their evolution.
This study showed that individual lesions were able to increase
their size exponentially thanks to the massive attraction of neu-
trophils. The presence of different lesions together meant that
large lesions (up to 8mm in diameter) could form within a
week (Marzo et al., 2013) (Figure 1B). What was crucial was the
rapid and massive entry of neutrophils into each lesion, showing
that liquefaction is a consequence of an excessive inflamma-
tory response, but curiously is not the origin of the extracellular
growth of the bacilli; excessive initial neutrophilic infiltration
and Neutrophil extracellular traps (NETs) induction supports
the initial phases of extracellular bacillary growth (Marzo et al.,
2013). Interestingly enough, this phenomenon had already been
described by Laennaec, who claimed that both an intense inflam-
matory response and the coalescence of different lesions were
the origin of cavitated lesions, as far back as the 19th century
(Hamraoui, 2006).
The Dynamic Hypothesis of the nature of latent infection
(Cardona, 2009) suggests that constant endogenous reinfection
is needed for the bacilli to persist in tissue (Figure 2). A rein-
fection process that takes into account the special milieu at the
upper lobes, where the induction of liquefaction and cavitation
FIGURE 1 | Induction of cavitated lesions. The most important question
is how a granuloma with a diameter of about 0.5mm can increase in size to
around 25mm, which is the size required to start a cavity (A). The answer
lies in the murine C3HeB/FeJ infection model. In this model, the size of the
lesions increases quickly over around 12 days thanks to the massive
accumulation of neutrophils, which allows extracellular growth of the bacilli
(Marzo et al., 2013), and to the coalescence of some of these lesions (B).
The anti-inflammatory preventive intervention should avoid the excessive
growth of individual granulomas thus allowing the encapsulation process to
occur, and thus avoiding the coalescence and the cavity formation (C).
is possible. In agreement with the epidemiological data, this
Hypothesis highlights how the host’s drainage system is able to
eliminate those non-replicating bacilli that are able to resist both
the immune response and chemotherapy, thusmaking reinfection
much less likely with time. The presence of different lesions of a
similar age (Figure 1B) might be favored in the upper lobes due
to the lower density of the capillary network and the larger size of
the alveolar space (Glenny, 2009), both of which favor the local
accumulation of lesions (Figure 1B).
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FIGURE 2 | Life cycle of Mycobacterium tuberculosis in the lungs
according to the dynamic hypothesis (Cardona, 2009; Cardona and
Ivanyi, 2011). Modified figure from the original found in Cardona and Ivanyi
(2011). Published with the permission of both the author and the editor. (I)
After transmission by aerosol, M. tuberculosis settles in the alveoli. (II) M.
tuberculosis grows inside macrophages, causing their necrosis. These cells
cause an almost inexistent inflammatory response, and the liberated bacilli
are simply phagocytosed by neighboring macrophages, causing no lesion.
This phase, which we have named “unicellular” (I), allows the bacilli
complete freedom to constantly cause new infectious foci, even in those
hosts that have optimal cellular immune responses. This is because, as they
do not induce an inflammatory response, these original foci cannot be
detected by specific lymphocytes. Once the inflammatory response is
sufficiently intense due to the large number of neighboring infected
macrophages, cellular traffic between the alveolar space and the capillary
allows drainage of the bacilli toward the lymphatic vessels and regional
lymph nodes, where antigenic presentation and lymphocytic proliferation
take place (II). These lymphocytes are attracted to the inflammatory foci,
where they activate the infected macrophages and destroy the bulk of the
bacilli (around 90%); the survivors become non-replicating and rest inside
activated macrophages or necrotic tissue (III). Once bacillary growth has
been controlled, the “cleaning” phase starts. This phase is characterized by
phagocytosis of the necrotic debris by the activated macrophages, which
retain even more non-replicating bacilli and become “foamy” by
accumulating cellular debris (IV). These foamy macrophages are then
progressively drained with the alveolar fluid toward the bronchi, where they
are destroyed. The bacilli contained therein pass into internal aerosols (V)
and are able to reinfect tissue (VI), although they are mainly drained toward
the intestinal tract (VI). This cycle can be interrupted by encapsulation, which
isolates the granuloma. This process occurs as a result of the intralobar
septae, which contain fibroblasts that are very sensitive to the mechanical
changes caused by intraparenchymal lesions (IVb). Some hosts can develop
an intense neutrophilic response, which is the origin of cavitated lesions (IVc).
MODELING THE ROLE OF THE DIFFERENT CELL-TYPES
INTERVENTION IN THE INFLAMMATORY RESPONSE MIGHT
BE A CHANCE FOR A FUTURE THERAPEUTIC
INTERVENTIONS AGAINST TB
As shown in the Figure 2 different cell types interact with
M. tuberculosis, thus being responsible for the neutrophilic
attraction. This aspect has been extensively reviewed recently
(Lowe et al., 2012). Briefly, the attraction of the neutrophils at
the site of infection is seen at very early stages, attracted by dif-
ferent chemo-attractant cytokines or chemokines synthetized by
alveolar macrophages, epithelial cells, γδ T cells or themselves.
Th17 cells do so in the immune phase. Interestingly, as recently
reviewed, IL-17 acts as an effector molecule similar to IFN-γ
after BCG vaccination and M. tuberculosis infection, contributing
to protection against active TB depending or not on IFN-γ (Li
et al., 2012). So far, the role of neutrophils have been fluctuating
between its beneficiary role both by directly killing the bacilli or
modulating a bactericidal destruction in macrophages; or dele-
terious by disseminating the infection, being even considered as
a “Trojan horse” (Lowe et al., 2012). The direct deleterious role
demonstrated by our group has not been considered so far, thus
giving a total new view in the field(Marzo et al., 2013).
The concept of modulating the inflammation to achieve a bet-
ter outcome in TB patients is not new, as is a common practice
in daily clinical management of certain forms of TB and under
certain conditions (meningitis, pericarditis, TB immune recon-
stitution inflammatory syndrome)(Lawn et al., 2013). In fact, an
extensive review has been published regarding this topic, tak-
ing into account the potential use of pro-inflammatory agents,
including therapeutic vaccines, immunosuppression agents to
reduce inflammation, and effector cytokines to enhance micro-
bicidal effects, all of them in different phases of development.
The conclusion is that pro-inflammatory or anti-inflammatory
adjuvants can be given, depending on the background of the
patient. Overall indicating that an individualized diagnosis and
pattern recognition analysis must be done in order to use the best
combination (Uhlin et al., 2012).
Taking into account the paramount role of neutrophil infiltra-
tion in the evolution of the infection toward disease, our group
has used the Kramnik-like experimental model to assay the use
of non-steroidal anti-inflammatory drugs (NSAIDs) both in a
preventive and therapeutic way, showing a clear beneficial pro-
file in terms of reduction of the lung infiltration, reduction of
bacillary load and increase in the survival time (Vilaplana et al.,
2013). Considering the wide use and experience in those kind of
drugs and the strong security profile, the inclusion of NSAIDs
could be easily extended to all TB patients, and especially in those
MDR and XDR were the physical progression of the lesions is that
important that needs surgical interventions (Ivanyi and Zumla,
2013). In this regard, we do believe that the induction of a bal-
anced immune response is paramount. This is able to avoid an
excessive inflammatory response that lead to a self-growing cycle
of bacillary growth that potentiates the inflammatory response,
which finally induces cavitation.
Finally, these findings also support the concept of some
sort of genetic predisposition of the host to develop such an
excessive non-proportional inflammatory response (Tobin and
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Ramakrishnan, 2008) (Figure 2). This could give lead to diagnos-
tic tool that would allow the susceptible population to be identi-
fied and, as such, several recent studies have identified remarkable
differences between infection and disease in terms of inflamma-
tory response, mainly related to the neutrophil population (Berry
et al., 2010).
CONCLUSION
After reviewing the current status of experimental modeling in TB
and attempting to consider the findings from a clinical viewpoint,
the lack of sufficient information concerning the induction of liq-
uefaction as a key mechanism in the induction of TBD becomes
clear. Interestingly, a known model in mice (the Kramnik-like
model) appoints to a reliable explanation for this process and
suggests that the inflammatory response might play an impor-
tant role on it. More resources should be dedicated to explore
these concepts as well to promote more studies including mod-
eling experiments using large mammals to better mimic human
tuberculosis.
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